| Release date: September 2007 Expiration date: September 30, 2008 Estimated time to complete activity: 1.5 hours |
Read through all material and click "Begin Activity" at the bottom of the page. |
Sponsored by
Support for this activity has been provided through an educational grant from
Activity Overview
This case-based activity is designed to outline effective management strategies for patients with hepatitis C virus (HCV) infection. Optimizing HCV patient outcome requires a thorough understanding of the underlying patient and disease factors that influence treatment. Clinical scenarios are presented, and through the use of case studies, faculty review and discuss current data to illustrate treatment decisions.
Target Audience
This activity has been designed to meet the educational needs of physicians and other health care professionals involved in the care of patients with chronic hepatitis C.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify HCV patients who may benefit from extended or truncated pegylated interferon (PEG-IFN) + ribavirin (RBV) treatment based on genotype, ethnicity, viral load, and the rapidity of viral clearance
- Describe the clinical relevance of rapid virologic response (RVR), early virologic response (EVR), and sustained virologic response (SVR) with respect to treatment duration and treatment goals
- Describe the influence of obesity, metabolic syndrome, and steatosis on HCV disease progression and treatment outcome
- Formulate an appropriate treatment strategy for HCV patients who are obese
Ira M. Jacobson, MD View biography
Vincent Astor Professor of Clinical Medicine
Chief, Division of Gastroenterology and Hepatology
Weill Medical College of Cornell University
Attending Physician
New York Presbyterian Hospital
New York, New York
John G. McHutchison, MD View biography
Associate Director, Duke Clinical Research Institute
Director, GI/Hepatology Research Program
Professor of Medicine
Division of Gastroenterology
Duke University Medical Center
Durham, North Carolina
FACULTY
Bruce R. Bacon, MD View biography
James F. King, MD Endowed Chair in Gastroenterology
Professor of Internal Medicine
Director, Division of Gastroenterology and Hepatology
Saint Louis University School of Medicine
St. Louis, Missouri
Kimberly A. Brown, MD View biography
Chief, Division of Gastroenterology and Hepatology
Henry Ford Hospital and Health System
Detroit, Michigan
Stuart C. Gordon, MD View biography
Associate Professor, Internal Medicine
Wayne State University
Director, Division of Hepatology and Hepatology Research
Henry Ford Hospital and Health System
Detroit, Michigan
Stephen A. Harrison, MD View biography
Chief of Hepatology
Associate Program Director, GI Fellowship
Brooke Army Medical Center
Fort Sam Houston, Texas
Accreditation Statement
Curatio CME Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Curatio CME Institute designates this educational activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physicians should not claim credit for this activity if credit was previously claimed for the symposium on which this Web activity is based.
Method of Participation
There are no fees for participating in this CME activity. To receive credit during the period September 2007 to September 30, 2008, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, (3) complete the posttest, and (4) complete the activity evaluation form, including the certificate information section.
Participants will then be able to print their AMA PRA Category 1 certificate for this activity.
Medium
The Internet was selected as the instructional format to accommodate the learning preferences of a significant portion of the target audience.
Disclosure
In accordance with the ACCME’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
Ira M. Jacobson, MD has disclosed the following relevant financial relationships:
| Grant/Research Support: | Coley Pharmaceutical Group, Gilead Sciences, GlobeImmune, Idenix Pharmaceuticals, Intermune, Schering-Plough Corporation, Valeant Pharmaceuticals, Vertex Pharmaceuticals |
| Consultant/Advisor: | Bristol-Myers Squibb, Coley Pharmaceutical Group, Gilead Sciences, GlaxoSmithKline, GlobeImmune, Human Genome Sciences, Idenix Pharmaceuticals, InterMune, Merck, Novartis, Pfizer, Schering-Plough Corporation, Valeant Pharmaceuticals, Vertex Pharmaceuticals |
| Speakers Bureau: | Bristol-Myers Squibb, Gilead Sciences, Schering-Plough Corporation, TAP Pharmaceutical Products |
Dr. Jacobson discusses the unlabeled or investigational use of a commercial product.
John G. McHutchison, MD has disclosed the following relevant financial relationships:
| Grant/Research Support: | Anadys Pharmaceuticals, Coley Pharmaceutical Group, First Circle Medical, GlaxoSmithKline, GlobeImmune, Human Genome Sciences, Idenix Pharmaceuticals, Intarcia Therapeutics, Novartis, Pfizer, Salix Pharmaceuticals, Sanofi-Aventis, Schering-Plough Corporation, Valeant Pharmaceuticals, Vertex Pharmaceuticals |
| Consultant: | Anadys Pharmaceuticals, Biolex Therapeutics, Coley Pharmaceutical Group, Epiphany Biosciences, First Circle Medical, GlaxoSmithKline, Human Genome Sciences, Idenix Pharmaceuticals, Idera Pharmaceuticals, Intarcia Therapeutics, InterMune, National Genetics Institute, Novartis, Peregrine, Pfizer, Schering-Plough Corporation, United Therapeutics, Valeant Pharmaceuticals, Vertex Pharmaceuticals, Wyeth |
Dr. McHutchison discusses the unlabeled or investigational use of a commercial product.
Bruce R. Bacon, MD has disclosed the following relevant financial relationships:
| Speaker: | Gilead Sciences, Schering-Plough Corporation |
| Consultant: | Coley Pharmaceutical Group, ISIS, Schering-Plough Corporation, Valeant Pharmaceuticals |
| Research Support: | Axcan Pharma, Bristol-Myers Squibb, Coley Pharmaceutical Group, Gilead Sciences, GlaxoSmithKline, ISIS, NIH, Novartis, Roche Laboratories, Valeant Pharmaceuticals |
| Advisory Board: | GlaxoSmithKline, Novartis |
Dr. Bacon discusses the unlabeled or investigational use of a commercial product.
Kimberly A. Brown, MD has disclosed the following relevant financial relationships:
| Speaker: | CLD, Gilead Sciences, Schering-Plough Corporation, Roche Laboratories |
Dr. Brown discusses the unlabeled or investigational use of a commercial product.
Steven A. Harrison, MD has disclosed the following relevant financial relationships:
| Speaker: | Bristol-Myers Squibb, Roche Laboratories, Schering-Plough Corporation |
| Consultant: | Bristol-Myers Squibb, Idenix Pharmaceuticals, Valeant Pharmaceuticals, Vertex Pharmaceuticals |
| Research Support: | Bristol-Myers Squibb, Idenix Pharmaceuticals, Roche Laboratories, Schering-Plough Corporation, Valeant Pharmaceuticals, Vertex Pharmaceuticals |
Dr. Gordon discusses the unlabeled or investigational use of a commercial product.
Stuart C. Gordon, MD has disclosed the following relevant financial relationships:
| Speaker: | Schering-Plough Corporation, Roche Laboratories, Valeant Pharmaceuticals |
| Consultant: | Roche Laboratories, Valeant Pharmaceuticals |
| Research Support: | Schering-Plough Corporation, Roche Laboratories, Valeant Pharmaceuticals |
Curatio CME Institute Staff
Denise C. LaTemple, PhD, Vice President, Scientific Services, has disclosed no relevant financial relationships.
Brett Mutschler, CME Director, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Managing Editor, has disclosed no relevant financial relationships.
Disclaimer
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute and Schering-Plough Corporation do not recommend the use of any agent outside the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Curatio CME Institute or Schering-Plough Corporation. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Hardware/Software Requirements
- Javascript-enabled browser
- Active internet connection
- Adobe Acrobat Reader
- Adobe Flash Player plugin v.8.0+
Privacy Policy
Curatio CME Institute collects the information provided by the user. The information is used to notify users about upcoming programs and educational information that may be of interest. The information is not shared or used for commercial purposes unless prior permission has been granted by the user.
Curatio CME Institute may collect standard Web traffic data such as time and date of visit. Curatio CME Institute uses this information to administer its Web site. Browsing activity is recorded to form aggregate and anonymous demographic information, which is used as described above. Curatio CME Institute does not sell or offer to sell any user data, including registration and billing information, to any third parties for commercial purposes. Curatio CME Institute does, when required, provide the minimum subset of information to third parties that are responsible for accreditation of and issuance of certification for CME/CE tests. By participating in the Web-based activity, the user agrees that Curatio CME Institute has full permission to provide this minimum subset of information to the third parties as required by law.
For CME questions, please contact cmeinfo@curatiocme.com or call (610) 363-1619 ext. 113. If you experience technical difficulties, please contact helpdesk@axis-healthcare.com.